About This Event

OKYO Pharma Ltd (Nasdaq: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic and often severe nerve-related pain but without an FDA-approved therapy, visits the Nasdaq MarketSite in Times Square.

In honor of the occasion, Gabriele Cerrone, Executive Chairman and Founder rings the Opening Bell.